Eurofins Scientific ended FY 16 on a strong note (highest organic growth since 2008), although investors accustomed to a guidance beat (the company has historically reported above guidance results) were disappointed with the ‘in-line’ results – the stock slumped c.6% immediately post the announcement, before partially recovering to close down 2%. Revenue was up 30% yoy to €2.5bn, in line with our estimate. The growth of 30% was a mix of organic growth of 9% and acquisit
23 Mar 2017
Strong top-line growth but margin progression remains slow
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong top-line growth but margin progression remains slow
Eurofins Scientific SE (ESF:WBO) | 0 0 1.6% | Mkt Cap: 8,723m
- Published:
23 Mar 2017 -
Author:
Jyoti Prakash -
Pages:
3
Eurofins Scientific ended FY 16 on a strong note (highest organic growth since 2008), although investors accustomed to a guidance beat (the company has historically reported above guidance results) were disappointed with the ‘in-line’ results – the stock slumped c.6% immediately post the announcement, before partially recovering to close down 2%. Revenue was up 30% yoy to €2.5bn, in line with our estimate. The growth of 30% was a mix of organic growth of 9% and acquisit